BRPI0508703B8 - processo para a síntese de um antagonista de cxcr4 - Google Patents

processo para a síntese de um antagonista de cxcr4

Info

Publication number
BRPI0508703B8
BRPI0508703B8 BRPI0508703A BRPI0508703A BRPI0508703B8 BR PI0508703 B8 BRPI0508703 B8 BR PI0508703B8 BR PI0508703 A BRPI0508703 A BR PI0508703A BR PI0508703 A BRPI0508703 A BR PI0508703A BR PI0508703 B8 BRPI0508703 B8 BR PI0508703B8
Authority
BR
Brazil
Prior art keywords
protected
synthesis
compound
amine
imine
Prior art date
Application number
BRPI0508703A
Other languages
English (en)
Inventor
Gauthier David
Chen Gang
R Baird Ian
B Crawford Jason
T Skerlj Renato
R Wilson Trevor
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of BRPI0508703A publication Critical patent/BRPI0508703A/pt
Publication of BRPI0508703B1 publication Critical patent/BRPI0508703B1/pt
Publication of BRPI0508703B8 publication Critical patent/BRPI0508703B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

processo para a síntese de um antagonista de cxcr4. a presente invenção refere-se a um process o para a sintetizar composto farmacêutico heterocíclico o qual liga ao receptor de quimiocina cxcr4. em uma modalidade, processo compreende: a) reagir uma 5,6,7,8- tetraidroquinolinilamina e um alquil aldeído portando uma ftalimida ou um grupo protetor de di-terc-butoxicarbonila (di-boc) para formar uma imina: b) reduzir a imina para formar uma amina secundária;c) a reagir a amina secundária com um composto heterocíclico substituído com haloalquila, para formar uma amina terciária protegida com ftalimido ou protegida com di-tercbutoxicarbonila, e d) hidrolisar a amina protegida para obter um composto tendo fórmula i'
BRPI0508703A 2004-03-15 2005-03-11 processo para a síntese de um antagonista de cxcr4 BRPI0508703B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55358904P 2004-03-15 2004-03-15
US60/553,589 2004-03-15
PCT/US2005/008268 WO2005090308A1 (en) 2004-03-15 2005-03-11 Process for the synthesis of a cxcr4 antagonist

Publications (3)

Publication Number Publication Date
BRPI0508703A BRPI0508703A (pt) 2007-08-07
BRPI0508703B1 BRPI0508703B1 (pt) 2020-11-24
BRPI0508703B8 true BRPI0508703B8 (pt) 2021-05-25

Family

ID=34993619

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508703A BRPI0508703B8 (pt) 2004-03-15 2005-03-11 processo para a síntese de um antagonista de cxcr4

Country Status (13)

Country Link
US (1) US7332605B2 (pt)
EP (1) EP1730113B1 (pt)
JP (1) JP4870660B2 (pt)
KR (1) KR20060131899A (pt)
CN (1) CN1930127B (pt)
AU (1) AU2005224079A1 (pt)
BR (1) BRPI0508703B8 (pt)
CA (1) CA2558389C (pt)
ES (1) ES2614508T3 (pt)
IL (1) IL177511A (pt)
NO (1) NO20064200L (pt)
RU (1) RU2006136381A (pt)
WO (1) WO2005090308A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
PE20060646A1 (es) * 2004-08-16 2006-08-04 Smithkline Beecham Corp Derivados de bencimidazol como moduladores de la actividad de quimioquinas
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
AR059197A1 (es) * 2006-01-25 2008-03-19 Smithkline Beecham Corp Derivados de indazolo piridina para el tratamiento de hiv
WO2007087548A2 (en) * 2006-01-25 2007-08-02 Smithkline Beecham Corporation Chemical compounds
JP2009545620A (ja) * 2006-08-02 2009-12-24 ジェンザイム・コーポレーション 併用療法
WO2008134326A1 (en) * 2007-04-26 2008-11-06 Dow Global Technologies Inc. Novel aldehyde composition
FR2934859B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
GB201604213D0 (en) * 2016-03-11 2016-04-27 Proximagen Ltd Drug combination and its use in therapy
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
BR112022022243A2 (pt) 2020-05-01 2022-12-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19.
JP2024538727A (ja) * 2021-10-07 2024-10-23 エックス４ ファーマシューティカルズ， インコーポレイテッド マボリキサフォルの合成およびその中間体
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质
WO2024216075A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2024216095A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2024216114A1 (en) * 2023-04-13 2024-10-17 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
IL133212A (en) * 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
RU2289581C2 (ru) * 2000-09-15 2006-12-20 Анормед, Инк. Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение
KR20030034184A (ko) * 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
CZ10903U1 (en) * 2001-01-11 2001-02-19 Oldrich Ing Cihak Bladed water wheel
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
CN1930127A (zh) 2007-03-14
IL177511A0 (en) 2006-12-10
KR20060131899A (ko) 2006-12-20
NO20064200L (no) 2006-09-15
JP2007529526A (ja) 2007-10-25
ES2614508T3 (es) 2017-05-31
EP1730113A4 (en) 2009-12-02
EP1730113B1 (en) 2016-12-28
US7332605B2 (en) 2008-02-19
JP4870660B2 (ja) 2012-02-08
BRPI0508703A (pt) 2007-08-07
IL177511A (en) 2010-12-30
EP1730113A1 (en) 2006-12-13
CN1930127B (zh) 2012-11-21
US20050209277A1 (en) 2005-09-22
RU2006136381A (ru) 2008-04-27
WO2005090308A1 (en) 2005-09-29
BRPI0508703B1 (pt) 2020-11-24
CA2558389C (en) 2013-10-08
AU2005224079A1 (en) 2005-09-29
CA2558389A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
BRPI0508703A (pt) processo para a sìntese de um antagonista de cxcr4
BRPI0500585B8 (pt) processo para a síntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
ATE402945T1 (de) Neuer steroidagonist für fxr
BRPI0500480A (pt) processo para a sìntese de (1s)-4,5-dimetóxi- 1-(metilaminometil)-benzociclobutano e sais de adição deste, e aplicação na sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
BR0116379A (pt) Antagonistas de receptor y5 de neuropeptìdeo y de uréia de heteroarila
BRPI0519262A2 (pt) derivados de pirazol fundidos e mÉtodos de tratamento de distérbios metabàlicos-relacionados destes
BRPI0606319A2 (pt) compostos farmacêuticos
BRPI0804091B8 (pt) compostos de 1,2,4,5-tetrahidro-3h-benzazepina, processo para sua preparação e composições farmacêuticas que os contêm
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
ATE303399T1 (de) Steroide als agonisten für fxr
BRPI0606455A (pt) compostos farmacêuticos
BRPI0518360A2 (pt) composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
DE60235396D1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
ATE414703T1 (de) Isoxazolderivate als inverse gaba a alpha5 agonisten
BR0314132A (pt) Processo para a fabricação de valsartan
BRPI0519287A2 (pt) derivados de amida
BRPI0516904A (pt) processo para a preparação de um derivado de 2-etilaminopiridina e composto
BRPI0414738A (pt) derivados de ácido acético substituìdos
ATE449082T1 (de) (3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
BRPI0519291A2 (pt) derivados de n[(4,5-difenil-3-alquil-2-tienil) metil] amina (amida, sulfonamida, carbamato e urÉia) como antagonistas dos receptores cb1 dos canabinàides
BRPI0500590A (pt) Processo para a sìntese de compostos de 1,3,4,5-tetraidro-2h-3-benzazepin-2-ona, e aplicação na sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2870 DE 06-01-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.